Nanjing Libowei Pharmaceutical Co., Ltd.

Primary study objective: To evaluate the efficacy of YK-1169 in the treatment of complicated intra-abdominal infection/bloodstream infection caused by carbapenem-resistant Gram-negative bacteria. Secondary study objective: To evaluate the safety of YK-1169 in the treatment of complicated intra-abdominal infection/bloodstream infection caused by carbapenem-resistant Gram-negative bacteria.

It is planned to conduct a randomized, single-blind, dose-escalation, placebo-controlled tolerance, pharmacokinetics and drug interaction study in healthy subjects to evaluate the safety and tolerability of single and multiple doses of YK-1169 in healthy subjects, the pharmacokinetic characteristics of single and multiple doses in healthy subjects, and the drug interaction between cefepime and avibactam.